X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Vicra is developed by Dr. Reddy, a copy of Jardiance (empagliflozin) is inhibitor of SGLT2 used as an adjunct to diet and exercise to improve glycemic control. Dr. Reddy's is expected to sell the drug in India at less than third of price charged by Boehringer Ingelheim.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vicra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
Details:
Jardiance (empagliflozin) is an oral inhibitor of sodium-glucose co-transporter 2 (SGLT2) inhibitor, which is being evaluated for the treatment of myocardial infarction.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2024
Details:
IVA337 (lanifibranor) is an orally-available small molecule that acts by activating all three peroxisome proliferator activated receptor (PPAR) isoforms. It is being evaluated for the treatment of Nonalcoholic Steatohepatitis and Diabetes Mellitus, Type 2.
Lead Product(s): Lanifibranor,Empagliflozin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA337
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
Jardiance (empagliflozin) is an oral inhibitor of sodium-glucose co-transporter 2 (SGLT2) inhibitor, which is indicated for the treatment of chronic kidney disease.
Lead Product(s): Empagliflozin
Therapeutic Area: Nephrology Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
BI 690517 is a novel selective aldosterone synthase inhibitor (ASi). It is under phase 2 clinical development for the treatment of chronic kidney disease.
Lead Product(s): BI 690517,Empagliflozin
Therapeutic Area: Nephrology Product Name: BI 690517
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2023
Details:
Jardiance® (empagliflozin) is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Lead Product(s): Empagliflozin
Therapeutic Area: Endocrinology Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2023
Details:
Jardiance (empagliflozin) is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion for chronic kidney disease.
Lead Product(s): Empagliflozin
Therapeutic Area: Endocrinology Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Details:
Jardiance (empagliflozin) is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion for chronic kidney disease.
Lead Product(s): Empagliflozin
Therapeutic Area: Endocrinology Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2023
Details:
Jardiance (empagliflozin) is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Lead Product(s): Empagliflozin
Therapeutic Area: Endocrinology Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
Empagliflozin works by inhibiting the sodium-glucose co-transporter-2 (SGLT-2) found in the proximal tubules in the kidneys. Through SGLT2 inhibition, empagliflozin reduces renal reabsorption of glucose and increases urinary excretion of glucose.
Lead Product(s): Empagliflozin
Therapeutic Area: Nephrology Product Name: Empagliflozin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2023
Details:
Jardiance® (empagliflozin) is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Lead Product(s): Empagliflozin
Therapeutic Area: Endocrinology Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2023
Details:
Jardiance® (empagliflozin) is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
Jardiance (empagliflozin) is an inhibitor of the sodium-glucose co-transporter 2 (SGLT2), which leads in lowering renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Lead Product(s): Empagliflozin
Therapeutic Area: Nephrology Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
Jardiance (empagliflozin) is an oral, once-daily, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in its label in several countries.
Lead Product(s): Empagliflozin
Therapeutic Area: Endocrinology Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
JARDIANCE (empagliflozin) is a prescription medicine used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, when the heart cannot pump enough blood to the rest of your body.
Lead Product(s): Empagliflozin
Therapeutic Area: Nephrology Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2022
Details:
Empagliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in people with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally).
Lead Product(s): Empagliflozin
Therapeutic Area: Endocrinology Product Name: Empagliflozin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
IVA337 (lanifibranor), orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory, beneficial vascular and metabolic changes in body by activating all PPAR isoforms, which are well‑characterized nuclear receptor proteins that regulate gene expression.
Lead Product(s): Lanifibranor,Empagliflozin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA337
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
Jardiance (empagliflozin) showed a reduction in relative risk of all-cause mortality by 40% compared with DPP-4 inhibitor in the subset of people with Medicare coverage.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Jardiance (empagliflozin) showed a reduction in relative risk of all-cause mortality by 40% compared with DPP-4 inhibitors in the subset of people with Medicare coverage.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2022
Details:
Jardiance (empagliflozin) is the top selling drug of BI in India, used in treatment of type-2 diabetes and for the treatment of heart failure with reduced ejection fraction (HFrEF).
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
Lanifibranor, a pan-PPAR agonist, improves markers of cardiometabolic health in patients with NASH, has demonstrated beneficial effects on liver histology, NASH resolution and fibrosis improvement in patients.
Lead Product(s): Lanifibranor,Empagliflozin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA337
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
The EMPA-KIDNEY trial, evaluating the effect of Jardiance® (empagliflozin), a prescription medicine in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial's Independent Data Monitoring Committee.
Lead Product(s): Empagliflozin
Therapeutic Area: Nephrology Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
Jardiance (empagliflozin), is an oral, once-daily, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in its label in several countries.
Lead Product(s): Empagliflozin
Therapeutic Area: Nephrology Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
Phase IIb has demonstrated that IVA337 (lanifibranor) as a monotherapy could not only resolve NASH and improve fibrosis but also improve lipids and glycemic profiles, in combination with empagliflozin provide additional benefits and further improve cardiometabolic risk profile.
Lead Product(s): Lanifibranor,Empagliflozin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA337
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
The breakthrough approval expands the existing indication of Jardiance® to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2022
Details:
Adults hospitalized for acute heart failure were 36% more likely to experience a clinical benefit over 90 days if initiated on Jardiance® (empagliflozin) following stabilization and prior to discharge compared with placebo in the phase III EMPULSE trial.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
U.S.FDA has approved Jardiance (empagliflozin), first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2022
Details:
The primary objective of the study is to demonstrate that the simultaneous initiation and combined use of finerenone and empagliflozin is superior to either empagliflozin alone, or finerenone alone, in reducing urine albumin-to-creatinine ratio (UACR).
Lead Product(s): Finerenone,Empagliflozin
Therapeutic Area: Nephrology Product Name: Kerendia
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2022
Details:
In the trial, Jardiance® (empagliflozin) demonstrated an impressive 21% relative risk reduction (3.3% absolute risk reduction, 0.79 HR, 0.69-0.90 95% CI) for the composite primary endpoint of cardiovascular death or hospitalization for heart failure.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2022
Details:
Jardiance is currently indicated to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure and reduced ejection fraction.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021
Details:
Jardiance consistently improved cardiovascular outcomes and slowed kidney function decline across the full range of kidney function down to an eGFR of 20 mL/min/1.73 m. Jardiance was well tolerated regardless of the level of baseline kidney function.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2021
Details:
Jardiance® (empagliflozin) has been granted marketing authorization by Health Canada as a treatment for heart failure with reduced ejection fraction (HFrEF), as an adjunct to standard of care therapy.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2021
Details:
Jardiance (empagliflozin) is an oral diabetes medicine that helps control blood sugar levels. Empagliflozin works by helping the kidneys get rid of glucose from your bloodstream.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2021
Details:
Designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with preserved ejection fraction.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2021
Details:
The EMPEROR chronic heart failure studies were two Phase III, randomized, double-blind trials that investigated once-daily empagliflozin compared to placebo in adults with chronic HFrEF or HFpEF, with or without diabetes.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2021
Details:
In this clinical first for adults with heart failure with preserved ejection fraction, empagliflozin demonstrated an impressive 21 percent relative risk reduction in the composite primary endpoint of cardiovascular death or hospitalization for heart failure.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2021
Details:
Participants were randomized to once-daily Jardiance 10 mg (n=1,863) or placebo (n=1,867), on top of treatment with guideline-directed heart failure therapy. Median follow-up time was 16 months.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2021
Details:
Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause mortality, hospitalization for heart failure and acute kidney injury requiring dialysis, compared to DPP-4 inhibitors.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2021
Details:
Marketing authorization is based on results from the EMPEROR-Reduced trial in which empagliflozin showed a significant 25 percent reduction in the combined relative risk versus placebo of cardiovascular death or hospitalization due to heart failure.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2021
Details:
The positive opinion is based on results from the EMPEROR-Reduced trial in which empagliflozin showed a significant 25 percent reduction in the combined relative risk of cardiovascular death or hospitalization due to heart failure.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2021
Details:
The sNDA is based on results from the EMPEROR-Reduced phase III trial, in which Jardiance was associated with a significant 25% relative risk reduction in the primary composite endpoint of time to cardiovascular death or hospitalization due to heart failure.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021
Details:
Lupin has received tentative approval for its Empagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, from the U.S FDA, to market a generic equivalent of Synjardy® XR Tablets.
Lead Product(s): Empagliflozin,Metformin
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
Jardiance reduced the risk of adverse cardiovascular and kidney events in adults with heart failure with reduced ejection fraction – with and without diabetes – regardless of CKD status at baseline.
Lead Product(s): Empagliflozin
Therapeutic Area: Nephrology Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2020
Details:
This Fast Track designation for empagliflozin emphasizes the urgent need for potential treatments that may improve outcomes following an acute myocardial infarction, more commonly known as a heart attack, in adults with and without diabetes.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2020
Details:
Full results from EMPEROR-Reduced phase III trial of Jardiance® (empagliflozin) in adults with heart failure with reduced ejection fraction, with and without diabetes, showed a significant 25% relative risk reduction in primary endpoint of time to cardiovascular death.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BI10773
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2020
Details:
Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2020
Details:
Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BI10773
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
The collaboration will investigate whether Jardiance® (empagliflozin) can improve outcomes and prevent heart failure in adults with and without diabetes who have had an acute myocardial infarction, commonly known as a heart attack.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 26, 2020
Details:
The PK results showed no impact of dorzagliatin and empagliflozin on respective PK properties under co-administration, supporting the us of this combination in the clinical setting.
Lead Product(s): Dorzagliatin,Empagliflozin
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2020
Details:
The EMPA-KIDNEY clinical study is evaluating Jardiance for the progression of kidney disease and the occurrence of cardiovascular death in adults with established CKD with and without diabetes.
Lead Product(s): Empagliflozin
Therapeutic Area: Nephrology Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
